Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Equillium Inc
0FYCurrent price
1.16 EUR
0 EUR (0.00%)
Last closed
0.75 USD
Company
equilliumbio.com
ISIN
US29446K1060
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
29 402 252 USD
Yield for 12 month
+53.10 %
1Y
3Y
5Y
10Y
15Y
0FY
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. Equillium, Inc. has a research collaboration agreement with Vivtex Corporation to develop GI-targeted formulations for Bi-specific peptide therapy. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. Address: 2223 Avenida De La Playa, La Jolla, CA, United States, 92037
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
5.75 USDP/E ratio
–Dividend Yield
–Current Year
+36 084 000 USD
Last Year
+15 759 000 USD
Current Quarter
+13 853 000 USD
Last Quarter
+10 689 000 USD
Current Year
+35 958 000 USD
Last Year
+15 641 000 USD
Current Quarter
+13 818 000 USD
Last Quarter
+10 657 000 USD
Key Figures 0FY
1 year
3 years
5 years
10 years
EBITDA
-9 584 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-11.95 %
PEG Ratio
–
Return On Equity TTM
-33.67 %
Wall Street Target Price
5.75 USD
Revenue TTM
42 623 000 USD
Book Value
0.63 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
51.8 %
Dividend Yield
–
Gross Profit TTM
15 759 000 USD
Earnings per share
-0.23 USD
Diluted Eps TTM
-0.23 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-19.51 %
Dividend Analytics 0FY
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 0FY
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 0FY
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
1.5314
Enterprise Value Revenue
0.3758
Price Sales TTM
0.6898
Enterprise Value EBITDA
0.0666
Price Book MRQ
1.3107
Financials 0FY
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 0FY
For 52 weeks
0.45 USD
3.25 USD
50 Day MA
0.97 USD
Shares Short Prior Month
190 494
200 Day MA
1.32 USD
Short Ratio
2.79
Shares Short
218 040
Short Percent
1 %
BeatStart